$PGNX Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in PROGENICS PHARMACEUTICALS INC.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in PROGENICS PHARMACEUTICALS INC. Get notifications about new insider transactions in PROGENICS PHARMACEUTICALS INC for free.
Page: < prev 1 2 3 4 5 6 7 ... 13 next >
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 03 2012 | PGNX | PROGENICS PHARMACE ... | ISRAEL ROBERT J | Senior VP Medical A ... | Sell | S | 9.85 | 1,000 | 9,852 | 38,383 | 39.4 K to 38.4 K (-2.54 %) |
| Apr 03 2012 | PGNX | PROGENICS PHARMACE ... | ISRAEL ROBERT J | Senior VP Medical A ... | Buy | M | 5.33 | 1,000 | 5,330 | 39,383 | 38.4 K to 39.4 K (+2.61 %) |
| Apr 27 2012 | PGNX | PROGENICS PHARMACE ... | Baker Mark Robert | CEO | Buy | P | 9.92 | 100 | 992 | 40,660 | 40.6 K to 40.7 K (+0.25 %) |
| Apr 27 2012 | PGNX | PROGENICS PHARMACE ... | Baker Mark Robert | CEO | Buy | P | 9.97 | 100 | 997 | 40,560 | 40.5 K to 40.6 K (+0.25 %) |
| Apr 27 2012 | PGNX | PROGENICS PHARMACE ... | Baker Mark Robert | CEO | Buy | P | 10.25 | 15 | 154 | 40,460 | 40.4 K to 40.5 K (+0.04 %) |
| Apr 27 2012 | PGNX | PROGENICS PHARMACE ... | Baker Mark Robert | CEO | Buy | P | 10.25 | 133 | 1,363 | 40,445 | 40.3 K to 40.4 K (+0.33 %) |
| Mar 29 2012 | PGNX | PROGENICS PHARMACE ... | Baker Mark Robert | CEO | Buy | P | 10.19 | 140 | 1,427 | 40,312 | 40.2 K to 40.3 K (+0.35 %) |
| Mar 29 2012 | PGNX | PROGENICS PHARMACE ... | Baker Mark Robert | CEO | Buy | P | 10.00 | 100 | 1,000 | 40,172 | 40.1 K to 40.2 K (+0.25 %) |
| Mar 29 2012 | PGNX | PROGENICS PHARMACE ... | Baker Mark Robert | CEO | Buy | P | 10.18 | 103 | 1,049 | 40,072 | 40 K to 40.1 K (+0.26 %) |
| Mar 05 2012 | PGNX | PROGENICS PHARMACE ... | Baker Mark Robert | CEO | Option Exercise | A | 9.81 | 33,334 | 327,007 | 100,000 | |
| Mar 05 2012 | PGNX | PROGENICS PHARMACE ... | Baker Mark Robert | CEO | Option Exercise | A | 9.81 | 66,666 | 653,993 | 66,666 | |
| Mar 05 2012 | PGNX | PROGENICS PHARMACE ... | MCKINNEY ROBERT A | Senior VP, CFO | Option Exercise | A | 9.81 | 50,000 | 490,500 | 50,000 | |
| Mar 05 2012 | PGNX | PROGENICS PHARMACE ... | Olson William C | Senior VP, Research ... | Option Exercise | A | 9.81 | 50,000 | 490,500 | 50,000 | |
| Mar 05 2012 | PGNX | PROGENICS PHARMACE ... | ISRAEL ROBERT J | Senior VP Medical A ... | Option Exercise | A | 9.81 | 50,000 | 490,500 | 50,000 | |
| Mar 02 2012 | PGNX | PROGENICS PHARMACE ... | ISRAEL ROBERT J | Senior VP Medical A ... | Option Exercise | M | 5.33 | 1,000 | 5,330 | 29,000 | |
| Mar 02 2012 | PGNX | PROGENICS PHARMACE ... | ISRAEL ROBERT J | Senior VP Medical A ... | Sell | S | 9.82 | 1,000 | 9,817 | 38,383 | 39.4 K to 38.4 K (-2.54 %) |
| Mar 02 2012 | PGNX | PROGENICS PHARMACE ... | ISRAEL ROBERT J | Senior VP Medical A ... | Buy | M | 5.33 | 1,000 | 5,330 | 39,383 | 38.4 K to 39.4 K (+2.61 %) |
| Feb 27 2012 | PGNX | PROGENICS PHARMACE ... | SCHEINBERG DAVID A | Director | Option Exercise | M | 6.90 | 1,250 | 8,625 | 0 | |
| Feb 27 2012 | PGNX | PROGENICS PHARMACE ... | SCHEINBERG DAVID A | Director | Option Exercise | M | 6.90 | 1,250 | 8,625 | 1,250 | |
| Feb 27 2012 | PGNX | PROGENICS PHARMACE ... | SCHEINBERG DAVID A | Director | Sell | S | 10.00 | 1,250 | 12,500 | 46,185 | 47.4 K to 46.2 K (-2.64 %) |
| Feb 27 2012 | PGNX | PROGENICS PHARMACE ... | SCHEINBERG DAVID A | Director | Buy | M | 6.90 | 1,250 | 8,625 | 47,435 | 46.2 K to 47.4 K (+2.71 %) |
| Feb 23 2012 | PGNX | PROGENICS PHARMACE ... | Baker Mark Robert | CEO | Buy | P | 9.54 | 1 | 10 | 39,969 | 40 K to 40 K (0.00 %) |
| Feb 23 2012 | PGNX | PROGENICS PHARMACE ... | Baker Mark Robert | CEO | Buy | P | 9.45 | 100 | 945 | 39,968 | 39.9 K to 40 K (+0.25 %) |
| Feb 23 2012 | PGNX | PROGENICS PHARMACE ... | Baker Mark Robert | CEO | Buy | P | 9.42 | 2 | 19 | 39,868 | 39.9 K to 39.9 K (+0.01 %) |
| Feb 23 2012 | PGNX | PROGENICS PHARMACE ... | Baker Mark Robert | CEO | Buy | P | 9.40 | 100 | 940 | 39,866 | 39.8 K to 39.9 K (+0.25 %) |
| Feb 23 2012 | PGNX | PROGENICS PHARMACE ... | Baker Mark Robert | CEO | Buy | P | 9.40 | 166 | 1,560 | 39,766 | 39.6 K to 39.8 K (+0.42 %) |
| Feb 03 2012 | PGNX | PROGENICS PHARMACE ... | BRINER KURT W | Director | Sell | S | 10.22 | 33,000 | 337,227 | 0 | 33 K to 0 (-100.00 %) |
| Feb 02 2012 | PGNX | PROGENICS PHARMACE ... | ISRAEL ROBERT J | Senior VP Medical A ... | Option Exercise | M | 5.33 | 1,000 | 5,330 | 30,000 | |
| Feb 02 2012 | PGNX | PROGENICS PHARMACE ... | ISRAEL ROBERT J | Senior VP Medical A ... | Sell | S | 9.48 | 1,000 | 9,478 | 38,383 | 39.4 K to 38.4 K (-2.54 %) |
| Feb 02 2012 | PGNX | PROGENICS PHARMACE ... | ISRAEL ROBERT J | Senior VP Medical A ... | Buy | M | 5.33 | 1,000 | 5,330 | 39,383 | 38.4 K to 39.4 K (+2.61 %) |
| Jan 26 2012 | PGNX | PROGENICS PHARMACE ... | Baker Mark Robert | CEO | Buy | P | 9.56 | 100 | 956 | 39,600 | 39.5 K to 39.6 K (+0.25 %) |
| Jan 26 2012 | PGNX | PROGENICS PHARMACE ... | Baker Mark Robert | CEO | Buy | P | 9.55 | 193 | 1,843 | 39,500 | 39.3 K to 39.5 K (+0.49 %) |
| Jan 26 2012 | PGNX | PROGENICS PHARMACE ... | Baker Mark Robert | CEO | Buy | P | 9.50 | 4 | 38 | 39,307 | 39.3 K to 39.3 K (+0.01 %) |
| Jan 26 2012 | PGNX | PROGENICS PHARMACE ... | Baker Mark Robert | CEO | Buy | P | 9.49 | 3 | 28 | 39,303 | 39.3 K to 39.3 K (+0.01 %) |
| Jan 26 2012 | PGNX | PROGENICS PHARMACE ... | Baker Mark Robert | CEO | Buy | P | 9.45 | 1 | 9 | 39,300 | 39.3 K to 39.3 K (0.00 %) |
| Jan 26 2012 | PGNX | PROGENICS PHARMACE ... | Baker Mark Robert | CEO | Buy | P | 9.45 | 63 | 595 | 39,299 | 39.2 K to 39.3 K (+0.16 %) |
| Jan 12 2012 | PGNX | PROGENICS PHARMACE ... | Baker Mark Robert | CEO | Buy | P | 8.87 | 200 | 1,774 | 39,236 | 39 K to 39.2 K (+0.51 %) |
| Jan 12 2012 | PGNX | PROGENICS PHARMACE ... | Baker Mark Robert | CEO | Buy | P | 8.86 | 191 | 1,692 | 39,036 | 38.8 K to 39 K (+0.49 %) |
| Jan 12 2012 | PGNX | PROGENICS PHARMACE ... | Baker Mark Robert | CEO | Buy | P | 6.50 | 76 | 494 | 38,211 | 38.1 K to 38.2 K (+0.20 %) |
| Jan 12 2012 | PGNX | PROGENICS PHARMACE ... | Baker Mark Robert | CEO | Buy | P | 6.52 | 455 | 2,967 | 38,135 | 37.7 K to 38.1 K (+1.21 %) |
| Jan 12 2012 | PGNX | PROGENICS PHARMACE ... | Baker Mark Robert | CEO | Buy | P | 6.53 | 1 | 7 | 37,680 | 37.7 K to 37.7 K (0.00 %) |
| Jan 04 2012 | PGNX | PROGENICS PHARMACE ... | ISRAEL ROBERT J | Senior VP Medical A ... | Option Exercise | M | 5.33 | 1,000 | 5,330 | 31,000 | |
| Jan 04 2012 | PGNX | PROGENICS PHARMACE ... | ISRAEL ROBERT J | Senior VP Medical A ... | Sell | S | 8.78 | 1,000 | 8,780 | 38,383 | 39.4 K to 38.4 K (-2.54 %) |
| Jan 04 2012 | PGNX | PROGENICS PHARMACE ... | ISRAEL ROBERT J | Senior VP Medical A ... | Buy | M | 5.33 | 1,000 | 5,330 | 39,383 | 38.4 K to 39.4 K (+2.61 %) |
| Dec 02 2011 | PGNX | PROGENICS PHARMACE ... | ISRAEL ROBERT J | Senior VP Medical A ... | Option Exercise | M | 5.33 | 1,000 | 5,330 | 32,000 | |
| Dec 02 2011 | PGNX | PROGENICS PHARMACE ... | ISRAEL ROBERT J | Senior VP Medical A ... | Sell | S | 6.66 | 1,000 | 6,660 | 38,383 | 39.4 K to 38.4 K (-2.54 %) |
| Dec 02 2011 | PGNX | PROGENICS PHARMACE ... | ISRAEL ROBERT J | Senior VP Medical A ... | Buy | M | 5.33 | 1,000 | 5,330 | 39,383 | 38.4 K to 39.4 K (+2.61 %) |
| Nov 28 2011 | PGNX | PROGENICS PHARMACE ... | Baker Mark Robert | CEO | Buy | S | 5.45 | 634 | 3,455 | 38,313 | 37.7 K to 38.3 K (+1.68 %) |
| Nov 01 2011 | PGNX | PROGENICS PHARMACE ... | ISRAEL ROBERT J | Senior VP Medical A ... | Option Exercise | M | 5.33 | 1,000 | 5,330 | 33,000 | |
| Nov 01 2011 | PGNX | PROGENICS PHARMACE ... | ISRAEL ROBERT J | Senior VP Medical A ... | Sell | S | 6.33 | 1,000 | 6,330 | 38,383 | 39.4 K to 38.4 K (-2.54 %) |
| Nov 01 2011 | PGNX | PROGENICS PHARMACE ... | ISRAEL ROBERT J | Senior VP Medical A ... | Buy | M | 5.33 | 1,000 | 5,330 | 39,383 | 38.4 K to 39.4 K (+2.61 %) |
| Oct 05 2011 | PGNX | PROGENICS PHARMACE ... | ISRAEL ROBERT J | Senior VP Medical A ... | Option Exercise | M | 5.33 | 1,000 | 5,330 | 34,000 | |
| Oct 05 2011 | PGNX | PROGENICS PHARMACE ... | ISRAEL ROBERT J | Senior VP Medical A ... | Sell | S | 6.33 | 1,000 | 6,330 | 38,383 | 39.4 K to 38.4 K (-2.54 %) |
| Oct 05 2011 | PGNX | PROGENICS PHARMACE ... | ISRAEL ROBERT J | Senior VP Medical A ... | Buy | M | 5.33 | 1,000 | 5,330 | 39,383 | 38.4 K to 39.4 K (+2.61 %) |
| Oct 04 2011 | PGNX | PROGENICS PHARMACE ... | Olson William C | Senior VP, Research ... | Option Exercise | M | 4.62 | 2,605 | 12,046 | 0 | |
| Oct 04 2011 | PGNX | PROGENICS PHARMACE ... | Olson William C | Senior VP, Research ... | Payment of Exercise | F | 5.44 | 2,356 | 12,817 | 46,774 | 49.1 K to 46.8 K (-4.80 %) |
| Oct 04 2011 | PGNX | PROGENICS PHARMACE ... | Olson William C | Senior VP, Research ... | Buy | M | 4.62 | 2,605 | 12,046 | 49,130 | 46.5 K to 49.1 K (+5.60 %) |
| Oct 04 2011 | PGNX | PROGENICS PHARMACE ... | MCKINNEY ROBERT A | Senior VP, CFO | Option Exercise | M | 4.62 | 2,737 | 12,656 | 0 | |
| Oct 04 2011 | PGNX | PROGENICS PHARMACE ... | MCKINNEY ROBERT A | Senior VP, CFO | Payment of Exercise | F | 5.44 | 2,475 | 13,464 | 44,415 | 46.9 K to 44.4 K (-5.28 %) |
| Oct 04 2011 | PGNX | PROGENICS PHARMACE ... | MCKINNEY ROBERT A | Senior VP, CFO | Buy | M | 4.62 | 2,737 | 12,656 | 46,890 | 44.2 K to 46.9 K (+6.20 %) |
| Oct 04 2011 | PGNX | PROGENICS PHARMACE ... | ISRAEL ROBERT J | Senior VP Medical A ... | Option Exercise | M | 4.62 | 3,638 | 16,822 | 0 | |
| Oct 04 2011 | PGNX | PROGENICS PHARMACE ... | ISRAEL ROBERT J | Senior VP Medical A ... | Payment of Exercise | F | 5.44 | 3,290 | 17,898 | 38,383 | 41.7 K to 38.4 K (-7.89 %) |
| Oct 04 2011 | PGNX | PROGENICS PHARMACE ... | ISRAEL ROBERT J | Senior VP Medical A ... | Buy | M | 4.62 | 3,638 | 16,822 | 41,673 | 38 K to 41.7 K (+9.56 %) |
| Oct 04 2011 | PGNX | PROGENICS PHARMACE ... | Baker Mark Robert | CEO | Option Exercise | M | 4.62 | 5,124 | 23,693 | 0 | |
| Oct 04 2011 | PGNX | PROGENICS PHARMACE ... | Baker Mark Robert | CEO | Payment of Exercise | F | 5.44 | 4,666 | 25,383 | 37,679 | 42.3 K to 37.7 K (-11.02 %) |
| Oct 04 2011 | PGNX | PROGENICS PHARMACE ... | Baker Mark Robert | CEO | Buy | M | 4.62 | 5,124 | 23,693 | 42,345 | 37.2 K to 42.3 K (+13.77 %) |
| Sep 28 2011 | PGNX | PROGENICS PHARMACE ... | Baker Mark Robert | CEO | Buy | P | 6.38 | 15 | 96 | 37,029 | 37 K to 37 K (+0.04 %) |
| Sep 28 2011 | PGNX | PROGENICS PHARMACE ... | Baker Mark Robert | CEO | Buy | P | 6.39 | 527 | 3,368 | 37,014 | 36.5 K to 37 K (+1.44 %) |
| Sep 28 2011 | PGNX | PROGENICS PHARMACE ... | ISRAEL ROBERT J | Senior VP Medical A ... | Option Exercise | M | 5.33 | 746 | 3,976 | 35,000 | |
| Sep 28 2011 | PGNX | PROGENICS PHARMACE ... | ISRAEL ROBERT J | Senior VP Medical A ... | Sell | S | 6.33 | 746 | 4,722 | 37,843 | 38.6 K to 37.8 K (-1.93 %) |
| Sep 28 2011 | PGNX | PROGENICS PHARMACE ... | ISRAEL ROBERT J | Senior VP Medical A ... | Buy | M | 5.33 | 746 | 3,976 | 38,589 | 37.8 K to 38.6 K (+1.97 %) |
| Sep 21 2011 | PGNX | PROGENICS PHARMACE ... | ISRAEL ROBERT J | Senior VP Medical A ... | Option Exercise | M | 5.33 | 100 | 533 | 35,746 | |
| Sep 21 2011 | PGNX | PROGENICS PHARMACE ... | ISRAEL ROBERT J | Senior VP Medical A ... | Sell | S | 6.33 | 100 | 633 | 37,843 | 37.9 K to 37.8 K (-0.26 %) |
| Sep 21 2011 | PGNX | PROGENICS PHARMACE ... | ISRAEL ROBERT J | Senior VP Medical A ... | Buy | M | 5.33 | 100 | 533 | 37,943 | 37.8 K to 37.9 K (+0.26 %) |
| Aug 25 2011 | PGNX | PROGENICS PHARMACE ... | Baker Mark Robert | CEO | Buy | P | 6.08 | 571 | 3,472 | 36,487 | 35.9 K to 36.5 K (+1.59 %) |
| Sep 06 2011 | PGNX | PROGENICS PHARMACE ... | ISRAEL ROBERT J | Senior VP Medical A ... | Option Exercise | M | 5.33 | 154 | 821 | 35,846 | |
| Sep 06 2011 | PGNX | PROGENICS PHARMACE ... | ISRAEL ROBERT J | Senior VP Medical A ... | Sell | S | 6.33 | 154 | 975 | 37,843 | 38 K to 37.8 K (-0.41 %) |
| Sep 06 2011 | PGNX | PROGENICS PHARMACE ... | ISRAEL ROBERT J | Senior VP Medical A ... | Buy | M | 5.33 | 154 | 821 | 37,997 | 37.8 K to 38 K (+0.41 %) |
| Aug 12 2011 | PGNX | PROGENICS PHARMACE ... | ISRAEL ROBERT J | Senior VP Medical A ... | Option Exercise | M | 5.33 | 1,000 | 5,330 | 36,000 | |
| Aug 12 2011 | PGNX | PROGENICS PHARMACE ... | ISRAEL ROBERT J | Senior VP Medical A ... | Sell | S | 6.33 | 1,000 | 6,330 | 37,843 | 38.8 K to 37.8 K (-2.57 %) |
| Aug 12 2011 | PGNX | PROGENICS PHARMACE ... | ISRAEL ROBERT J | Senior VP Medical A ... | Buy | M | 5.33 | 1,000 | 5,330 | 38,843 | 37.8 K to 38.8 K (+2.64 %) |
| Jul 28 2011 | PGNX | PROGENICS PHARMACE ... | Baker Mark Robert | CEO | Buy | P | 6.12 | 567 | 3,472 | 35,916 | 35.3 K to 35.9 K (+1.60 %) |
| Jul 06 2011 | PGNX | PROGENICS PHARMACE ... | SCHEINBERG DAVID A | Director | Option Exercise | A | 7.40 | 10,000 | 74,000 | 10,000 | |
| Jul 06 2011 | PGNX | PROGENICS PHARMACE ... | WILLIAMS NICOLE | Director | Option Exercise | A | 7.40 | 10,000 | 74,000 | 10,000 | |
| Jul 06 2011 | PGNX | PROGENICS PHARMACE ... | BRINER KURT W | Director | Option Exercise | A | 7.40 | 10,000 | 74,000 | 10,000 | |
| Jul 06 2011 | PGNX | PROGENICS PHARMACE ... | MADDON PAUL J | CSO&ViceChairmanBOD | Option Exercise | A | 7.40 | 85,000 | 629,000 | 85,000 | |
| Jul 06 2011 | PGNX | PROGENICS PHARMACE ... | GOFF STEPHEN P | Director | Option Exercise | A | 7.40 | 10,000 | 74,000 | 10,000 | |
| Jul 06 2011 | PGNX | PROGENICS PHARMACE ... | DALTON MARK F | Director | Option Exercise | A | 7.40 | 10,000 | 74,000 | 10,000 | |
| Jul 06 2011 | PGNX | PROGENICS PHARMACE ... | Crowley Peter J | Director | Option Exercise | A | 7.40 | 40,000 | 296,000 | 40,000 | |
| Jul 06 2011 | PGNX | PROGENICS PHARMACE ... | BAKER CHARLES A | Director | Option Exercise | A | 5.35 | 10,000 | 53,500 | 10,000 | |
| Jul 06 2011 | PGNX | PROGENICS PHARMACE ... | Olson William C | Senior VP, Research ... | Option Exercise | A | 7.40 | 70,000 | 518,000 | 70,000 | |
| Jul 06 2011 | PGNX | PROGENICS PHARMACE ... | Olson William C | Senior VP, Research ... | Option Exercise | M | 5.46 | 6,335 | 34,589 | 0 | |
| Jul 06 2011 | PGNX | PROGENICS PHARMACE ... | Olson William C | Senior VP, Research ... | Payment of Exercise | F | 7.40 | 5,276 | 39,042 | 46,333 | 51.6 K to 46.3 K (-10.22 %) |
| Jul 06 2011 | PGNX | PROGENICS PHARMACE ... | Olson William C | Senior VP, Research ... | Buy | M | 5.46 | 6,335 | 34,589 | 51,609 | 45.3 K to 51.6 K (+13.99 %) |
| Jul 06 2011 | PGNX | PROGENICS PHARMACE ... | MCKINNEY ROBERT A | Senior VP, CFO | Option Exercise | A | 7.40 | 70,000 | 518,000 | 70,000 | |
| Jul 06 2011 | PGNX | PROGENICS PHARMACE ... | MCKINNEY ROBERT A | Senior VP, CFO | Option Exercise | M | 5.46 | 7,279 | 39,743 | 0 | |
| Jul 06 2011 | PGNX | PROGENICS PHARMACE ... | MCKINNEY ROBERT A | Senior VP, CFO | Payment of Exercise | F | 7.40 | 6,062 | 44,859 | 43,961 | 50 K to 44 K (-12.12 %) |
| Jul 06 2011 | PGNX | PROGENICS PHARMACE ... | MCKINNEY ROBERT A | Senior VP, CFO | Buy | M | 5.46 | 7,279 | 39,743 | 50,023 | 42.7 K to 50 K (+17.03 %) |
| Jul 06 2011 | PGNX | PROGENICS PHARMACE ... | ISRAEL ROBERT J | Senior VP Medical A ... | Option Exercise | A | 7.40 | 70,000 | 518,000 | 70,000 | |
| Jul 06 2011 | PGNX | PROGENICS PHARMACE ... | ISRAEL ROBERT J | Senior VP Medical A ... | Option Exercise | M | 5.33 | 1,000 | 5,330 | 37,000 | |
| Jul 06 2011 | PGNX | PROGENICS PHARMACE ... | ISRAEL ROBERT J | Senior VP Medical A ... | Option Exercise | M | 5.46 | 8,322 | 45,438 | 0 | |
| Jul 06 2011 | PGNX | PROGENICS PHARMACE ... | ISRAEL ROBERT J | Senior VP Medical A ... | Payment of Exercise | F | 7.40 | 6,930 | 51,282 | 37,843 | 44.8 K to 37.8 K (-15.48 %) |
| Jul 06 2011 | PGNX | PROGENICS PHARMACE ... | ISRAEL ROBERT J | Senior VP Medical A ... | Buy | M | 5.46 | 8,322 | 45,438 | 44,773 | 36.5 K to 44.8 K (+22.83 %) |
| Jul 06 2011 | PGNX | PROGENICS PHARMACE ... | ISRAEL ROBERT J | Senior VP Medical A ... | Sell | S | 7.21 | 1,000 | 7,205 | 36,151 | 37.2 K to 36.2 K (-2.69 %) |
| Jul 06 2011 | PGNX | PROGENICS PHARMACE ... | ISRAEL ROBERT J | Senior VP Medical A ... | Buy | M | 5.33 | 1,000 | 5,330 | 37,151 | 36.2 K to 37.2 K (+2.77 %) |
| Jul 06 2011 | PGNX | PROGENICS PHARMACE ... | Baker Mark Robert | CEO | Option Exercise | A | 7.40 | 62,500 | 462,500 | 125,000 | |
| Jul 06 2011 | PGNX | PROGENICS PHARMACE ... | Baker Mark Robert | CEO | Option Exercise | A | 7.40 | 62,500 | 462,500 | 62,500 | |
| Jul 06 2011 | PGNX | PROGENICS PHARMACE ... | Baker Mark Robert | CEO | Option Exercise | M | 5.46 | 20,032 | 109,375 | 0 | |
| Jul 06 2011 | PGNX | PROGENICS PHARMACE ... | Baker Mark Robert | CEO | Payment of Exercise | F | 7.40 | 16,905 | 125,097 | 35,349 | 52.3 K to 35.3 K (-32.35 %) |
| Jul 06 2011 | PGNX | PROGENICS PHARMACE ... | Baker Mark Robert | CEO | Buy | M | 5.46 | 20,032 | 109,375 | 52,254 | 32.2 K to 52.3 K (+62.17 %) |
| Jun 24 2011 | PGNX | PROGENICS PHARMACE ... | Baker Mark Robert | CEO | Buy | P | 7.08 | 490 | 3,469 | 31,922 | 31.4 K to 31.9 K (+1.56 %) |
| Jun 22 2011 | PGNX | PROGENICS PHARMACE ... | ISRAEL ROBERT J | Senior VP Medical A ... | Sell | S | 7.02 | 7,889 | 55,341 | 36,151 | 44 K to 36.2 K (-17.91 %) |
| Jun 22 2011 | PGNX | PROGENICS PHARMACE ... | Olson William C | Senior VP, Research ... | Sell | S | 7.11 | 106 | 754 | 44,974 | 45.1 K to 45 K (-0.24 %) |
| Jun 22 2011 | PGNX | PROGENICS PHARMACE ... | Olson William C | Senior VP, Research ... | Sell | S | 7.09 | 2,766 | 19,605 | 45,080 | 47.8 K to 45.1 K (-5.78 %) |
| Jun 20 2011 | PGNX | PROGENICS PHARMACE ... | MCKINNEY ROBERT A | Senior VP, CFO | Sell | S | 7.50 | 3,000 | 22,500 | 42,444 | 45.4 K to 42.4 K (-6.60 %) |
| Jun 10 2011 | PGNX | PROGENICS PHARMACE ... | Baker Mark Robert | CEO | Option Exercise | A | 7.66 | 200,000 | 1,532,000 | 200,000 | |
| Jun 02 2011 | PGNX | PROGENICS PHARMACE ... | ISRAEL ROBERT J | Senior VP Medical A ... | Option Exercise | M | 5.33 | 1,000 | 5,330 | 38,000 | |
| Jun 02 2011 | PGNX | PROGENICS PHARMACE ... | ISRAEL ROBERT J | Senior VP Medical A ... | Sell | S | 8.15 | 1,000 | 8,153 | 44,040 | 45 K to 44 K (-2.22 %) |
| Jun 02 2011 | PGNX | PROGENICS PHARMACE ... | ISRAEL ROBERT J | Senior VP Medical A ... | Buy | M | 5.33 | 1,000 | 5,330 | 45,040 | 44 K to 45 K (+2.27 %) |
| May 26 2011 | PGNX | PROGENICS PHARMACE ... | Baker Mark Robert | CEO | Buy | P | 7.13 | 486 | 3,465 | 31,432 | 30.9 K to 31.4 K (+1.57 %) |
| May 17 2011 | PGNX | PROGENICS PHARMACE ... | BRINER KURT W | Director | Sell | S | 8.19 | 5,000 | 40,925 | 33,000 | 38 K to 33 K (-13.16 %) |
| May 17 2011 | PGNX | PROGENICS PHARMACE ... | BRINER KURT W | Director | Sell | S | 8.27 | 15,000 | 123,975 | 38,000 | 53 K to 38 K (-28.30 %) |
| May 04 2011 | PGNX | PROGENICS PHARMACE ... | ISRAEL ROBERT J | Sr. VP, Medical Aff ... | Option Exercise | M | 5.33 | 1,000 | 5,330 | 39,000 | |
| May 04 2011 | PGNX | PROGENICS PHARMACE ... | ISRAEL ROBERT J | Sr. VP, Medical Aff ... | Sell | S | 7.39 | 1,000 | 7,390 | 44,040 | 45 K to 44 K (-2.22 %) |
| May 04 2011 | PGNX | PROGENICS PHARMACE ... | ISRAEL ROBERT J | Sr. VP, Medical Aff ... | Buy | M | 5.33 | 1,000 | 5,330 | 45,040 | 44 K to 45 K (+2.27 %) |
| Apr 27 2011 | PGNX | PROGENICS PHARMACE ... | Baker Mark Robert | CEO | Buy | P | 7.24 | 479 | 3,468 | 30,946 | 30.5 K to 30.9 K (+1.57 %) |
| Apr 05 2011 | PGNX | PROGENICS PHARMACE ... | MCKINNEY ROBERT A | Chief Financial Off ... | Option Exercise | A | 6.18 | 2,161 | 13,355 | 2,161 | |
| Apr 05 2011 | PGNX | PROGENICS PHARMACE ... | MCKINNEY ROBERT A | Chief Financial Off ... | Option Exercise | M | 5.05 | 2,495 | 12,600 | 0 | |
| Apr 05 2011 | PGNX | PROGENICS PHARMACE ... | MCKINNEY ROBERT A | Chief Financial Off ... | Payment of Exercise | F | 6.29 | 2,181 | 13,718 | 45,444 | 47.6 K to 45.4 K (-4.58 %) |
| Apr 05 2011 | PGNX | PROGENICS PHARMACE ... | MCKINNEY ROBERT A | Chief Financial Off ... | Buy | M | 5.05 | 2,495 | 12,600 | 47,625 | 45.1 K to 47.6 K (+5.53 %) |
| Apr 05 2011 | PGNX | PROGENICS PHARMACE ... | Baker Mark Robert | President | Option Exercise | A | 6.18 | 4,045 | 24,998 | 4,045 | |
| Apr 05 2011 | PGNX | PROGENICS PHARMACE ... | Baker Mark Robert | President | Option Exercise | M | 5.05 | 4,022 | 20,311 | 0 | |
| Apr 05 2011 | PGNX | PROGENICS PHARMACE ... | Baker Mark Robert | President | Payment of Exercise | F | 6.29 | 3,550 | 22,330 | 30,467 | 34 K to 30.5 K (-10.44 %) |
| Apr 05 2011 | PGNX | PROGENICS PHARMACE ... | Baker Mark Robert | President | Buy | M | 5.05 | 4,022 | 20,311 | 34,017 | 30 K to 34 K (+13.41 %) |
| Apr 05 2011 | PGNX | PROGENICS PHARMACE ... | Olson William C | SR. VP, Research & ... | Option Exercise | A | 6.18 | 2,057 | 12,712 | 2,057 | |
| Apr 05 2011 | PGNX | PROGENICS PHARMACE ... | Olson William C | SR. VP, Research & ... | Option Exercise | M | 5.05 | 2,373 | 11,984 | 0 | |
| Apr 05 2011 | PGNX | PROGENICS PHARMACE ... | Olson William C | SR. VP, Research & ... | Payment of Exercise | F | 6.29 | 2,075 | 13,052 | 47,846 | 49.9 K to 47.8 K (-4.16 %) |
| Apr 05 2011 | PGNX | PROGENICS PHARMACE ... | Olson William C | SR. VP, Research & ... | Buy | M | 5.05 | 2,373 | 11,984 | 49,921 | 47.5 K to 49.9 K (+4.99 %) |
| Apr 05 2011 | PGNX | PROGENICS PHARMACE ... | ISRAEL ROBERT J | Sr. VP, Medical Aff ... | Option Exercise | M | 5.33 | 1,000 | 5,330 | 40,000 | |
| Apr 05 2011 | PGNX | PROGENICS PHARMACE ... | ISRAEL ROBERT J | Sr. VP, Medical Aff ... | Option Exercise | A | 6.18 | 2,872 | 17,749 | 2,872 | |
| Apr 05 2011 | PGNX | PROGENICS PHARMACE ... | ISRAEL ROBERT J | Sr. VP, Medical Aff ... | Option Exercise | M | 5.05 | 3,332 | 16,827 | 0 | |
| Apr 05 2011 | PGNX | PROGENICS PHARMACE ... | ISRAEL ROBERT J | Sr. VP, Medical Aff ... | Payment of Exercise | F | 6.29 | 2,913 | 18,323 | 44,040 | 47 K to 44 K (-6.20 %) |
| Apr 05 2011 | PGNX | PROGENICS PHARMACE ... | ISRAEL ROBERT J | Sr. VP, Medical Aff ... | Buy | M | 5.05 | 3,332 | 16,827 | 46,953 | 43.6 K to 47 K (+7.64 %) |
| Apr 05 2011 | PGNX | PROGENICS PHARMACE ... | ISRAEL ROBERT J | Sr. VP, Medical Aff ... | Sell | S | 6.33 | 1,000 | 6,330 | 43,377 | 44.4 K to 43.4 K (-2.25 %) |
| Apr 05 2011 | PGNX | PROGENICS PHARMACE ... | ISRAEL ROBERT J | Sr. VP, Medical Aff ... | Buy | M | 5.33 | 1,000 | 5,330 | 44,377 | 43.4 K to 44.4 K (+2.31 %) |
| Mar 30 2011 | PGNX | PROGENICS PHARMACE ... | ISRAEL ROBERT J | Sr. VP, Medical Aff ... | Option Exercise | M | 5.33 | 800 | 4,264 | 41,000 | |
| Mar 30 2011 | PGNX | PROGENICS PHARMACE ... | ISRAEL ROBERT J | Sr. VP, Medical Aff ... | Sell | S | 6.33 | 800 | 5,064 | 43,377 | 44.2 K to 43.4 K (-1.81 %) |
| Mar 30 2011 | PGNX | PROGENICS PHARMACE ... | ISRAEL ROBERT J | Sr. VP, Medical Aff ... | Buy | M | 5.33 | 800 | 4,264 | 44,177 | 43.4 K to 44.2 K (+1.84 %) |
| Mar 11 2011 | PGNX | PROGENICS PHARMACE ... | GOFF STEPHEN P | Director | Option Exercise | M | 1.33 | 32,500 | 43,225 | 0 | |
| Mar 11 2011 | PGNX | PROGENICS PHARMACE ... | GOFF STEPHEN P | Director | Buy | M | 1.33 | 32,500 | 43,225 | 66,000 | 33.5 K to 66 K (+97.01 %) |